Morocco’s Medicine Affordability Crisis Demands Urgent Action

What is driving high medicine prices in Morocco? Several official fact-finding missions have investigated the root causes behind this issue. Their findings highlight multiple contributing factors, with limited availability of generic medicines emerging as one of the most significant drivers. In other words, brand-name medicines account for a substantial share of medicines sold in Morocco, while lower-cost generic alternatives remain relatively limited, contributing to high medicine prices. 

The issue, however, transcends the price attached to a medicine at the pharmacy. Affordability is shaped by the entire structure of the pharmaceutical market, from how medicines are priced and approved to how they are distributed and how effectively competition is maintained. When one part of this system fails to function properly, the financial burden can ultimately shift to patients and their families. 

This is particularly important in a country where healthcare expenses can place considerable pressure on household budgets. For patients who require long-term treatment, even a seemingly manageable difference in the price of one medicine can become a substantial financial burden over months or years. The question of medicine affordability is therefore not simply a matter of market efficiency, but also a question of access to healthcare. 

What are we doing about it in Morocco? It is a multifaceted and complex issue, and the pricing and affordability system is improving one tick at a time. Morocco is in the process of strengthening its regulatory oversight, including through discussions held in July introducing new pricing rules for both locally produced and imported medicines. These reforms are promising and include measures to protect local production, address medicines’ shortages, among other initiatives. 

Strengthening local pharmaceutical production can play an important role in this effort. A stronger domestic industry can help reduce dependence on imports, improve the resilience of supply chains, and provide greater security when international disruptions affect the availability or cost of medicines. Yet local production alone cannot guarantee affordability. Without effective competition, transparent pricing, and timely access to alternatives, patients may continue to face high costs even in a market with a significant domestic manufacturing base. 

Patients cannot afford to wait for reform

Don’t get too excited, as there is no easy fix. Translating these reforms into improved access and affordability will not happen overnight.  The industry players are backed by well-resourced lobbying efforts and influence tactics aimed at preserving their profit margins. Thus, balancing the industry players’ interests with those of patients is time- and resource-consuming; it is also an exercise of continuous improvement in governance, enforcement, monitoring and political commitment to accountability. Any regulatory loophole can be exploited by market participants to stifle meaningful reforms, particularly when industry players push or cross the boundaries of legal and ethical conduct.

This does not mean that the interests of pharmaceutical companies should be disregarded. A viable pharmaceutical sector requires investment, research, manufacturing capacity, skilled workers, and predictable regulation. The challenge for policymakers is to ensure that protecting the sustainability of the industry does not come at the expense of patients who depend on affordable treatment. A functioning system must be capable of accommodating both objectives without allowing one to systematically outweigh the other.

While Morocco is advancing its medicine pricing and affordability framework, meaningful progress takes time. Unfortunately, patients cannot always afford to wait. For many, receiving the right medication at the right time is a matter of life and death. Still, some essential medicines remain expensive and are priced higher than in many other countries, causing those in need of treatment preventable misery and suffering. 

The generic medicine bottleneck

Beyond revising pricing rules and supporting local production, another key challenge to improving medicine affordability is the slow approval and administrative processes for low-cost generic applications in Morocco. Once the patents on brand-name medicines expire, manufacturers lose their exclusive right to produce and market these medicines. 

In principle, the expiration of a patent should open the door to competition. Generic manufacturers can enter the market with alternatives that contain the same active ingredients and can be offered at lower prices. The benefits of that competition, however, depend on how quickly those alternatives can obtain approval and reach pharmacies. If regulatory processes remain unnecessarily lengthy, the formal end of a patent does not necessarily translate into immediate competition for patients.

Competitors can then introduce low-cost alternatives. However, this is not always the case given the complex and lengthy approval process in Morocco. Such administrative inefficiencies can create conditions that eliminate or weaken competition. In particular, some brand-name medicines remain on the Moroccan market with high prices despite the expiration of their patents. When generic alternatives fail to make it to the market, patients are often left with no option but to make financial sacrifices or endure serious suffering.  

The significant price gaps for certain essential medicines between Morocco and other countries stand as strong evidence that competition rules are not effectively enforced. While little attention is paid to the human impact of these market dynamics on patients, such an environment can exploit people during their most fragile moments. 

Without strong checks and balances, patients are left to fight the industry’s deep pockets with bare hands. As you can imagine, this is a losing battle. Building strong pricing policies, transparency mechanisms, and accountability rules across government institutions and industry players is essential to breaking monopolies and laying the foundation for a more sustainable pricing strategy. In addition, accelerating the approval rate of generic medicine applications in Morocco and incentivizing generic manufacturers and distributors could help foster a more competitive marketplace. This, in return, could improve the affordability and accessibility of medicines.  

Ultimately, the success of Morocco’s medicine reforms should be measured not only by the regulations adopted, but by what patients experience at the pharmacy counter. A reform that looks effective on paper but leaves essential medicines unaffordable has failed to address the problem at its core. Morocco has an opportunity to build a pharmaceutical pricing system that supports local industry while putting competition, transparency, and patient access at the center of decision-making.